MWVC
AMAG

Morgens Waterfall Vintiadis & Co’s AMAG Pharmaceuticals AMAG Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-70,000
Closed -$4.83M – 52
2015
Q2 		$4.83M Hold
70,000
– – 3.04% 8
2015
Q1 		$3.83M Buy
+70,000
New +$3.34M 2.45% 18

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's AMAG Position: Q3 2015 in Review

Morgens Waterfall Vintiadis & Co sold out of AMAG Pharmaceuticals (AMAG) in Q3 2015, closing a stake of 70,000 shares — an estimated $4.83M sold.

Morgens Waterfall Vintiadis & Co first reported a position in AMAG in Q1 2015 and held it in 2 quarters. The position peaked at $4.83M in Q2 2015. 210 funds tracked by Wall St. Rank hold AMAG as of Q3 2015.

  • Morgens Waterfall Vintiadis & Co reported no remaining AMAG Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 70,000 AMAG Pharmaceuticals shares in Q3 2015, an estimated $4.83M.
  • Morgens Waterfall Vintiadis & Co first reported a position in AMAG Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Morgens Waterfall Vintiadis & Co's AMAG Pharmaceuticals position peaked at $4.83M in Q2 2015.
  • 210 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2015.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2015, filed 10 Nov 2015.